Mma Bana continued: AZT/3TC/LPV‐r showed no clear difference in stillbirths compared with AZT/3TC/ABC (low certainty).
Mma Bana continued: AZT/3TC/LPV‐r showed no clear difference in maternal Mortality at Six Months compared with AZT/3TC/ABC (low certainty).
Mma Bana continued: AZT/3TC/LPV‐r showed no clear difference in mother to Child Transmission In Utero Positive HIV DNA PCR Within 96… compared with AZT/3TC/ABC (low certainty).
Mma Bana continued: AZT/3TC/LPV‐r showed no clear difference in mother to Child Transmission Late Postpartum Negative HIV DNA PCR at… compared with AZT/3TC/ABC (low certainty).
Mma Bana continued: AZT/3TC/LPV‐r showed no clear difference in mother to Child Transmission at Six Months Post‐Partum All Positive… compared with AZT/3TC/ABC (low certainty).
It is very uncertain whether bae: AZT/3TC/NVP changes HIV‐Transmission or Death at 7 Months compared with AZT (+/‐ single dose NVP) (very low certainty).
It is very uncertain whether bae: AZT/3TC/NVP changes infant Grade 3/4 Severe Adverse Events at Birth compared with AZT (+/‐ single dose NVP) (very low certainty).
It is very uncertain whether bae: AZT/3TC/NVP changes prematurity compared with AZT (+/‐ single dose NVP) (very low certainty).
It is very uncertain whether bae: AZT/3TC/NVP changes mother to Child Transmission at Birth compared with AZT (+/‐ single dose NVP) (very low certainty).
Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Mortality at 6 Months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (moderate certainty).
It is very uncertain whether bae: AZT/3TC/NVP changes mother to Child Transmission at 1 Month compared with AZT (+/‐ single dose NVP) (very low certainty).
It is very uncertain whether bae: AZT/3TC/NVP changes mother to Child Transmission Cumulative by 7 Months compared with AZT (+/‐ single dose NVP) (very low certainty).
Marazzi: AZT/3TC/NVP for HIV Infection in Pregnant Women With CD4 <250 showed no clear difference in maternal Grade 3/4 Hepatotoxicity compared with >250 cells/mm3; GRADE not reported.
It is very uncertain whether phanuphak: AZT/3TC/NVP (PMTCT) changes maternal Grade 3/4 Severe Adverse Events compared with AZT/3TC/NVP (ART) (very low certainty).
Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Mortality at 12 months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes maternal Grade 3/4 Severe Adverse Events compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).
Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Grade 3/4 Severe Adverse Events compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes prematurity compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).
Kesho Bora continued: AZT/3TC/LPV‐r showed no clear difference in low Birth Weight compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
Kesho Bora continued: AZT/3TC/LPV‐r showed no clear difference in stillbirths compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).